Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923

Bats Are Natural Reservoirs of SARS-Like Coronaviruses

Li, W., Shi, Z., Yu, M., Ren, W., Smith, C. S., Epstein, J. H., Wang, H., Crameri, G. S., Hú, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,571

Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China

Guan, Y., Zheng, B., He, Y., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S., Li, P. H., Zhang, L., Guan, Y., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,404

Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor

Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,035

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome

Kuiken, T., Fouchier, R. A. M., Schutten, M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D. A. J., Laman, J. D., de Jong, T., van Doornum, G., Lim, W. W. L., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13967-0 · Cited by 1,015

Receptor and viral determinants of SARS‐coronavirus adaptation to human ACE2

Li, W., Zhang, C., Sui, J., Kuhn, J. H., Moore, M. J., Luo, S., Wong, S.-K., Huang, I., Xu, K., Vasilieva, N. Y., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600640 · Cited by 993

Immunosenescence: emerging challenges for an ageing population

Aw, D., Silva, A. B., & Palmer, D. B. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02555.x · Cited by 880

Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China

The Chinese SARS Molecular Epidemiology Consortium (2004) · Science · doi:10.1126/science.1092002 · Cited by 765

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697

An interferon‐γ‐related cytokine storm in SARS patients

Huang, K., Su, I., Theron, M., Wu, Y., Lai, S., Liu, C., & Lei, H. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20255 · Cited by 679

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

Song, Z., Xu, Y., Bao, L., Zhang, L., Yü, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,292

Potently neutralizing and protective human antibodies against SARS-CoV-2

Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041

A human monoclonal antibody blocking SARS-CoV-2 infection

Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F. G., & Bosch, B. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,128

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science · doi:10.1126/science.abe8499 · Cited by 900

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795

Structural insights into coronavirus entry

(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Crawford, K. H. D., Eguia, R. T., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 744

Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission

Graham, R. L., & Baric, R. S. (2009) · Journal of Virology · doi:10.1128/jvi.01394-09 · Cited by 753

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Hou, Y. J., Adams, L. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2708-8 · Cited by 675

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Walls, A. C., Tortorici, M. A., Snijder, J., Xiong, X., Bosch, B., Rey, F. A., & Veesler, D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708727114 · Cited by 520

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0998-x · Cited by 429

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.001 · Cited by 364

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 427

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 387

CoV-AbDab: the coronavirus antibody database

Raybould, M. I. J., Kovaltsuk, A., Marks, C., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa739 · Cited by 383

Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway

Jaume, M., Yip, M., Cheung, C. Y., Leung, N., Li, P. H., Kien, F., Dutry, I., Callendret, B., Escriou, N., Altmeyer, R. M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00671-11 · Cited by 312

Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice

Becker, M. M., Graham, R. L., Donaldson, E., Rockx, B., Sims, A. M., Sheahan, T. P., Pickles, R. J., Corti, D., Johnston, R. E., Baric, R. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808116105 · Cited by 260

Growth, detection, quantification, and inactivation of SARS-CoV-2

Case, J. B., Bailey, A. L., Kim, A. S., Chen, R. E., & Diamond, M. (2020) · Virology · doi:10.1016/j.virol.2020.05.015 · Cited by 234

An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

Erasmus, J. H., Khandhar, A. P., O’Connor, M. A., Walls, A. C., Hemann, E. A., Murapa, P., Archer, J., Leventhal, S., Fuller, J. T., Lewis, T. B., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9396 · Cited by 241

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

Tang, X.-C., Agnihothram, S. S., Jiao, Y., Stanhope, J., Graham, R. L., Peterson, E. C., Avnir, Y., Tallarico, A. S. C., Sheehan, J., Zhu, Q., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402074111 · Cited by 232

Structural basis for broad coronavirus neutralization

Sauer, M. M., Tortorici, M. A., Park, Y., Walls, A. C., Homad, L. J., Acton, O. J., Bowen, J. E., Wang, C., Xiong, X., de van der Schueren, W., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00596-4 · Cited by 175

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.015 · Cited by 185

Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection

Rockx, B., Baas, T., Zornetzer, G. A., Haagmans, B. L., Sheahan, T. P., Frieman, M. B., Dyer, M. D., Teal, T. H., Proll, S. C., van den Brand, J. M. A., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00127-09 · Cited by 176

Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing

Elshabrawy, H. A., Coughlin, M. M., Baker, S. C., & Prabhakar, B. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050366 · Cited by 173

Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference

Beigel, J. H., Nam, H. H., Adams, P. L., Krafft, A. E., Ince, W. L., El‐Kamary, S. S., & Sims, A. M. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.04.006 · Cited by 168

SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission

Deming, M. E., Donaldson, E., & Baric, R. S. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.012 · Cited by 166

Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

Chen, W., Hotez, P. J., & Bottazzi, M. E. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1740560 · Cited by 140

Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease

Netland, J., DeDiego, M. L., Zhao, J., Fett, C., Álvarez, E. A., Nieto-Torres, J. L., Enjuanes, L., & Perlman, S. M. (2010) · Virology · doi:10.1016/j.virol.2010.01.004 · Cited by 134

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Noy-Porat, T., Makdasi, E., Alcalay, R., Mechaly, A., Levy, Y., Bercovich-Kinori, A., Zauberman, A., Tamir, H., Yahalom-Ronen, Y., Israeli, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18159-4 · Cited by 122

Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control

Scheller, C., Krebs, F., Minkner, R., Astner, I., Gil‐Moles, M., & Wätzig, H. (2020) · Electrophoresis · doi:10.1002/elps.202000121 · Cited by 130

A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection

Li, T., Cai, H., Yao, H., Zhou, B., Zhang, N., van Vlissingen, M. F., Kuiken, T., Han, W., GeurtsvanKessel, C. H., Gong, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24905-z · Cited by 105

Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses

Agnihothram, S., Gopal, R., Yount, B. L., Donaldson, E., Menachery, V. D., Graham, R. L., Scobey, T., Gralinski, L. E., Denison, M. R., Zambon, M. C. F. A., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit609 · Cited by 104

The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses

Tse, L. V., Meganck, R. M., Graham, R. L., & Baric, R. S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00658 · Cited by 101

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV

Scheid, J. F., Barnes, C. O., Eraslan, B., Hudak, A., Keeffe, J. R., Cosimi, L. A., Brown, E., Muecksch, F., Weisblum, Y., Zhang, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.032 · Cited by 90

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential

Coughlin, M. M., & Prabhakar, B. S. (2011) · Reviews in Medical Virology · doi:10.1002/rmv.706 · Cited by 87

Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview

Khosroshahi, L. M., Rokni, M., Mokhtari, T., & Noorbakhsh, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107364 · Cited by 90

Structural Definition of a Neutralization-sensitive Epitope on the MERS-CoV S1-NTD

Wang, N., Rosen, O., Wang, L., Turner, H. L., Stevens, L. J., Corbett, K. S., Bowman, C. A., Pallesen, J., Shi, W., Zhang, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.052 · Cited by 86

Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology

Berry, J., & Gaudet, R. G. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.018 · Cited by 88

Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus

Yasui, F., Kohara, M., Kitabatake, M., Nishiwaki, T., Fujii, H., Tateno, C., Yoneda, M., Morita, K., Matsushima, K., Koyasu, S., et al. (2014) · Virology · doi:10.1016/j.virol.2014.02.005 · Cited by 83

Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus

Rockx, B., Donaldson, E., Frieman, M. B., Sheahan, T. P., Corti, D., Lanzavecchia, A., & Baric, R. S. (2010) · The Journal of Infectious Diseases · doi:10.1086/651022 · Cited by 84

Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions

Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H., & Sivaraman, J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.004 · Cited by 83

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit

Hurlburt, N. K., Homad, L. J., Sinha, I. R., Jennewein, M. F., MacCamy, A. J., Wan, Y.-H., Boonyaratanakornkit, J. B., Sholukh, A. M., Jackson, A. M., Zhou, P.-P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03262-7 · Cited by 80

Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway

Sui, J., Aird, D. R., Tamin, A., Murakami, A., Yan, M., Yammanuru, A., Jing, H., Kan, B., Liu, X., Zhu, Q. K., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000197 · Cited by 82

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies

Hussain, A., Hasan, A., Babadaei, M. M. N., Bloukh, S. H., Chowdhury, M. E. H., Sharifi, M., Haghighat, S., & Falahati, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110559 · Cited by 78

The heptad repeat region is a major selection target in MERS-CoV and related coronaviruses

Forni, D., Filippi, G., Cagliani, R., GIOIA, L. D., Pozzoli, U., Al‐Daghri, N. M., Clerici, M., & Sironi, M. (2015) · Scientific Reports · doi:10.1038/srep14480 · Cited by 76

The landscape of antibody binding in SARS-CoV-2 infection

Heffron, A. S., McIlwain, S. J., Amjadi, M. F., Baker, D. A., Khullar, S., Armbrust, T., Halfmann, P., Kawaoka, Y., Sethi, A. K., Palmenberg, A. C., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001265 · Cited by 78

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

Pinto, D., Park, Y., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., Marco, A. D., et al. (2020) · Worldwide Protein Data Bank · doi:10.2210/pdb6ws6/pdb · Cited by 82

Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects

Arashkia, A., Jalilvand, S., Mohajel, N., Afchangi, A., Azadmanesh, K., Salehi-Vaziri, ‪., Fazlalipour, M., Pouriayevali, M. H., Jalali, T., Nasab, S. D. M., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2183 · Cited by 73

Effects of Human Anti-Spike Protein Receptor Binding Domain Antibodies on Severe Acute Respiratory Syndrome Coronavirus Neutralization Escape and Fitness

Sui, J., Deming, M. E., Rockx, B., Liddington, R., Zhu, Q. K., Baric, R. S., & Marasco, W. A. (2014) · Journal of Virology · doi:10.1128/jvi.02232-14 · Cited by 68

Successful Vaccination Strategies That Protect Aged Mice from Lethal Challenge from Influenza Virus and Heterologous Severe Acute Respiratory Syndrome Coronavirus

Sheahan, T. P., Whitmore, A. C., Long, K. M., Ferris, M. T., Rockx, B., Funkhouser, W. K., Donaldson, E., Gralinski, L. E., Collier, M., Heise, M. T., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01805-10 · Cited by 69

Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics

Zhou, D., Tian, X., Qi, R., Peng, C., & Zhang, W. (2020) · Glycobiology · doi:10.1093/glycob/cwaa052 · Cited by 69

Pathways of Cross-Species Transmission of Synthetically Reconstructed Zoonotic Severe Acute Respiratory Syndrome Coronavirus

Sheahan, T. P., Rockx, B., Donaldson, E., Corti, D., & Baric, R. S. (2008) · Journal of Virology · doi:10.1128/jvi.00818-08 · Cited by 68

Primary Severe Acute Respiratory Syndrome Coronavirus Infection Limits Replication but Not Lung Inflammation upon Homologous Rechallenge

Clay, C. C., Donart, N., Fomukong, N. G., Knight, J. B., Lei, W., Price, L., Hahn, F. F., Westrienen, J. V., & Harrod, K. S. (2012) · Journal of Virology · doi:10.1128/jvi.06791-11 · Cited by 64

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individualPreprint

Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.12.091298 · Cited by 64

Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations

Ghorbani, M., Brooks, B. R., & Klauda, J. B. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c05994 · Cited by 61

Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody

Rosenfeld, R., Noy-Porat, T., Mechaly, A., Makdasi, E., Levy, Y., Alcalay, R., Falach, R., Aftalion, M., Epstein, E., Gur, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21239-8 · Cited by 55

An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review

Somasundaram, R., Choraria, A., & Antonysamy, M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106654 · Cited by 51

Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells

Corti, D., & Lanzavecchia, A. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0018-2014 · Cited by 49

Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases

Wang, X., Xia, S., Wang, Q., Xu, W., Li, W., Lu, L., & Jiang, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113843 · Cited by 46

Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19

Kumar, P., Sah, A., Tripathi, G., Kashyap, A., Tripathi, A., Rao, R., Mishra, P., Mallick, K. C. B., Husain, A., & Kashyap, M. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03924-2 · Cited by 40

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2

Konwarh, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01531 · Cited by 36

Substitution at Aspartic Acid 1128 in the SARS Coronavirus Spike Glycoprotein Mediates Escape from a S2 Domain-Targeting Neutralizing Monoclonal Antibody

Ng, O.-W., Keng, C. T., Leung, C. S.-W., Peiris, M. J. S., Poon, L. L. M., & Tan, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102415 · Cited by 35

Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments

Goodarzi, P., Mahdavi, F., Mirzaei, R., Hasanvand, H., Sholeh, M., Zamani, F., Sohrabi, M., Tabibzadeh, A., Jeda, A. S., Niya, M. H. K., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106885 · Cited by 33

A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics

Verma, J. K., & Subbarao, N. (2021) · Archives of Virology · doi:10.1007/s00705-021-04961-y · Cited by 32

The Spike of SARS-CoV-2: Uniqueness and Applications

Kumavath, R., Barh, D., Andrade, B. S., Imchen, M., Aburjaile, F. F., Ch, A., Rodrigues, D. L. N., Tiwari, S., Alzahrani, K. J., Goés‐Neto, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663912 · Cited by 34

Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms

Coughlin, M. M., Babcook, J. S., & Prabhakar, B. S. (2009) · Virology · doi:10.1016/j.virol.2009.07.028 · Cited by 31

Recent advances in antibody‐based immunotherapy strategies for COVID‐19

Esmaeilzadeh, A., Rostami, S. M., Yeganeh, P. M., Tahmasebi, S., & Ahmadi, M. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30017 · Cited by 29

Increased Antibody Affinity Confers Broad In Vitro Protection against Escape Mutants of Severe Acute Respiratory Syndrome Coronavirus

Rani, M., Deming, M. E., Donaldson, E., Blarcom, T. J. V., Baric, R. S., Iverson, B. L., & Georgiou, G. (2012) · Journal of Virology · doi:10.1128/jvi.00233-12 · Cited by 31

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primatesPreprint

Erasmus, J. H., Khandhar, A. P., Walls, A. C., Hemann, E. A., O’Connor, M. A., Murapa, P., Archer, J. F., Leventhal, S. S., Fuller, J., Lewis, T. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.28.121640 · Cited by 30

Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell–cell fusion

Thakur, N., Conceicao, C., Isaacs, A., Human, S., Modhiran, N., McLean, R. K., Pedrera, M., Tan, T. K., Rijal, P., Townsend, A., et al. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001506 · Cited by 25

Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses

Shinnakasu, R., Sakakibara, S., Yamamoto, H. H., Wang, P.-H., Moriyama, S., Sax, N., Ono, C., Yamanaka, A., Adachi, Y., Onodera, T., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211003 · Cited by 28

Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease

Davenport, B., Catala, A., Weston, S. M., Johnson, R. M., Ardanuy, J., Hammond, H., Dillen, C. A., Frieman, M. B., Catalano, C. E., & Morrison, T. E. (2022) · npj Vaccines · doi:10.1038/s41541-022-00481-1 · Cited by 28

Inhibitors of SARS-CoV entry – Identification using an internally-controlled dual envelope pseudovirion assay

Zhou, Y., Agudelo, J., Lü, K., Goetz, D. H., Hansell, E. J., Chen, Y., Roush, W. R., McKerrow, J. H., Craik, C. S., Amberg, S. M., et al. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.07.016 · Cited by 25

A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection

Tabll, A. A., Shahein, Y. E., Omran, M. M., Elnakib, M., Ragheb, A., & Amer, K. (2021) · Human Antibodies · doi:10.3233/hab-200441 · Cited by 24

Progress Towards Recombinant Anti-Infective Antibodies

Pai, J., Sutherland, J. N., & Maynard, J. A. (2009) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489109787236319 · Cited by 24

Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods

Ndzouboukou, J. B., Zhang, Y., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2470-7 · Cited by 23

A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infectionPreprint

Li, T., Cai, H., Yao, H., Zhou, B., Zhang, N., Gong, Y., Zhao, Y., Shen, Q., Qin, W., Hutter, C. A. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.09.143438 · Cited by 26

Neutralizing antibody against severe acute respiratory syndrome (SARS)‐coronavirus spike is highly effective for the protection of mice in the murine SARS model

Ishii, K., Hasegawa, H., Nagata, N., Ami, Y., Fukushi, S., Taguchi, F., & Tsunetsugu‐Yokota, Y. (2008) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00097.x · Cited by 20

How did we get here? Short history of COVID ‐19 and other coronavirus‐related epidemics

Lango, M. N. (2020) · Head & Neck · doi:10.1002/hed.26275 · Cited by 24

An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks

Kayode, A. J., Banji-Onisile, F. O., Olaniran, A. O., & Okoh, A. I. (2021) · Pathogens · doi:10.3390/pathogens10091108 · Cited by 23

A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV

Mitsuki, Y.-Y., Ohnishi, K., Takagi, H., Oshima, M., Yamamoto, T., Mizukoshi, F., Terahara, K., Kobayashi, K., Yamamoto, N., Yamaoka, S., et al. (2008) · Microbes and Infection · doi:10.1016/j.micinf.2008.05.009 · Cited by 21

Reconstitution of the receptor-binding motif of the SARS coronavirus

Freund, N. T., Roitburd‐Berman, A., Sui, J., Marasco, W. A., & Gershoni, J. M. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv052 · Cited by 19

Viral metagenomics, protein structure, and reverse genetics: Key strategies for investigating coronaviruses

Johnson, B. A., Graham, R. L., & Menachery, V. D. (2017) · Virology · doi:10.1016/j.virol.2017.12.009 · Cited by 19

The landscape of antibody binding in SARS-CoV-2 infectionPreprint

Heffron, A. S., McIlwain, S. J., Amjadi, M. F., Baker, D. A., Khullar, S., Sethi, A. K., Palmenberg, A. C., Shelef, M. A., O’Connor, D. H., & Ong, I. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.10.334292 · Cited by 16

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19Preprint

Rappazzo, C. G., Tse, L. V., Kaku, C. I., Wrapp, D., Sakharkar, M., Huang, D., Deveau, L. M., Yockachonis, T. J., Herbert, A. S., Battles, M. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.17.385500 · Cited by 16

Development and Characterization of Broadly Cross-reactive Monoclonal Antibodies Against All KnownEbolavirusSpecies

Hernandez, H., Marceau, C. D., Halliday, H., Callison, J. A., Borisevich, V., Escaffre, O., Creech, J., Feldmann, H., & Rockx, B. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv209 · Cited by 15

Identification of 22 N-glycosites on Spike Glycoprotein of SARS-CoV-2 and Accessible Surface Glycopeptide Motifs: Implications on Vaccination and Antibody TherapeuticsPreprint

Zhou, D., Qi, R., Zhang, W., Tian, X., & Peng, C. (2020) · Preprints.org · doi:10.20944/preprints202002.0381.v2 · Cited by 12

Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies

Noy-Porat, T., Edri, A., Alcalay, R., Makdasi, E., Gur, D., Aftalion, M., Evgy, Y., Beth-Din, A., Levy, Y., Epstein, E., et al. (2021) · Antibodies · doi:10.3390/antib10040045 · Cited by 10

Emerging Animal Coronaviruses: First SARS and Now MERS

Fong, I. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-50890-0_4 · Cited by 12

“Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry

Shukla, S. P., Cho, K. B., Rustagi, V., Gao, X., Fu, X., Zhang, S., Guo, B., & Udugamasooriya, D. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168963 · Cited by 12

Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus

Corti, D., Lanzavecchia, A., Frieman, M. B., Sheahan, T. P., Donaldson, E., Baric, R. S., & Rockx, B. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/kpdt-nn47

Development and Characterization of a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice

Greenough, T. C., Babcock, G. J., Roberts, A., Hernández, H. J., Thomas, W. D., Coccia, J. A., Graziano, R. F., Srinivasan, M., Lowy, I., Finberg, R. W., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/427242 · Cited by 156

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

ter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S.-W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 599

Structural insights into human monoclonal antibodies with pan-coronavirus reactivity

Barnes, C. O., & Abernathy, M. E. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.210.supp.234.08

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885